Published in Blood on December 27, 2002
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood (2013) 1.52
Malaria, erythrocytic infection, and anemia. Hematology Am Soc Hematol Educ Program (2009) 1.44
Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood (2007) 1.19
Sickle red cell-endothelium interactions. Microcirculation (2009) 1.12
Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood (2011) 1.00
Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease. Haematologica (2010) 0.96
Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype. Genomics Insights (2009) 0.96
Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood (2015) 0.96
Sickle cell disease: selected aspects of pathophysiology. Clin Hemorheol Microcirc (2010) 0.95
Pathophysiological insights in sickle cell disease. Indian J Med Res (2011) 0.93
Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med (2007) 0.93
The Laminin 511/521-binding site on the Lutheran blood group glycoprotein is located at the flexible junction of Ig domains 2 and 3. Blood (2007) 0.88
Heterogeneous red blood cell adhesion and deformability in sickle cell disease. Sci Rep (2014) 0.87
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood (2016) 0.87
Intercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium. Haematologica (2009) 0.85
Adhesive activity of Lu glycoproteins is regulated by interaction with spectrin. Blood (2008) 0.85
Effect of propranolol as antiadhesive therapy in sickle cell disease. Clin Transl Sci (2012) 0.83
Epinephrine modulates BCAM/Lu and ICAM-4 expression on the sickle cell trait red blood cell membrane. Biophys J (2012) 0.81
AKAP-dependent modulation of BCAM/Lu adhesion on normal and sickle cell disease RBCs revealed by force nanoscopy. Biophys J (2014) 0.80
Pathophisiology of sickle cell disease and new drugs for the treatment. Mediterr J Hematol Infect Dis (2009) 0.80
Inhibition of erythrocyte "apoptosis" by catecholamines. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.80
Computational biomechanics of human red blood cells in hematological disorders. J Biomech Eng (2016) 0.80
An antibody to the lutheran glycoprotein (Lu) recognizing the LU4 blood type variant inhibits cell adhesion to laminin α5. PLoS One (2011) 0.79
MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo. PLoS One (2014) 0.78
Increased erythrocyte adhesion to VCAM-1 during pulsatile flow: Application of a microfluidic flow adhesion bioassay. Clin Hemorheol Microcirc (2015) 0.78
Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation. J Biol Chem (2014) 0.78
Biomechanics and biorheology of red blood cells in sickle cell anemia. J Biomech (2016) 0.76
Emerging point-of-care technologies for sickle cell disease screening and monitoring. Expert Rev Med Devices (2016) 0.75
Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease. Transl Res (2016) 0.75
Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs via AKAPs Is Revealed by AFM. Biophys J (2017) 0.75
Asthma management in sickle cell disease. Biomed Res Int (2013) 0.75
Biomarkers and recent advances in the management and therapy of sickle cell disease. F1000Res (2015) 0.75
Developing new pharmacotherapeutic approaches to treating sickle-cell disease. ISBT Sci Ser (2016) 0.75
Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol (2006) 3.02
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol (2010) 2.55
Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood (2009) 2.50
Alterations of the CIB2 calcium- and integrin-binding protein cause Usher syndrome type 1J and nonsyndromic deafness DFNB48. Nat Genet (2012) 2.43
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood (2010) 2.34
Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol (2008) 2.32
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA (2010) 2.25
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol (2006) 2.06
Pulmonary hypertension in sickle cell disease. Am J Med (2004) 1.76
MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol (2011) 1.67
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica (2008) 1.67
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood (2008) 1.61
The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One (2008) 1.60
Relationships between Rap1b, affinity modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton. J Biol Chem (2002) 1.59
Release of cellular UDP-glucose as a potential extracellular signaling molecule. Mol Pharmacol (2003) 1.53
Hypercoagulability in sickle cell disease: a curious paradox. Am J Med (2003) 1.47
Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. Cell Host Microbe (2012) 1.45
Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am (2006) 1.44
Essential role of CIB1 in regulating PAK1 activation and cell migration. J Cell Biol (2005) 1.38
Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica (2009) 1.36
Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol (2010) 1.34
Structural and biochemical characterization of CIB1 delineates a new family of EF-hand-containing proteins. J Biol Chem (2004) 1.29
Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood (2008) 1.28
Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol (2010) 1.28
Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol (2014) 1.27
Impaired adenosine-5'-triphosphate release from red blood cells promotes their adhesion to endothelial cells: a mechanism of hypoxemia after transfusion. Crit Care Med (2011) 1.26
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol (2010) 1.25
Quantitative microscopy and nanoscopy of sickle red blood cells performed by wide field digital interferometry. J Biomed Opt (2011) 1.23
CIB1 is a regulator of pathological cardiac hypertrophy. Nat Med (2010) 1.20
Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood (2007) 1.19
Molecular basis of CIB binding to the integrin alpha IIb cytoplasmic domain. J Biol Chem (2002) 1.18
Delayed hemolytic transfusion reaction in sickle cell disease. Am J Med Sci (2010) 1.18
CIB1 is essential for mouse spermatogenesis. Mol Cell Biol (2006) 1.17
Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood (2004) 1.17
Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. Blood (2009) 1.13
Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol (2007) 1.13
Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood (2012) 1.12
The unique N-terminus of R-ras is required for Rac activation and precise regulation of cell migration. Mol Biol Cell (2005) 1.11
Phase I study of eptifibatide in patients with sickle cell anaemia. Br J Haematol (2007) 1.09
CIB1 is an endogenous inhibitor of agonist-induced integrin alphaIIbbeta3 activation. J Cell Biol (2006) 1.09
A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol (2012) 1.09
Mechanism of CD47-induced alpha4beta1 integrin activation and adhesion in sickle reticulocytes. J Biol Chem (2004) 1.08
Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood (2002) 1.08
Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol (2013) 1.08
Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion (2008) 1.06
Functional redundancy of SWI/SNF catalytic subunits in maintaining vascular endothelial cells in the adult heart. Circ Res (2012) 1.06
Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood (2008) 1.05
A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia. PLoS One (2012) 1.04
CIB1 regulates endothelial cells and ischemia-induced pathological and adaptive angiogenesis. Circ Res (2007) 1.04
Cytokines and plasma factors in sickle cell disease. Curr Opin Hematol (2007) 1.03
Tickling the tails: cytoplasmic domain proteins that regulate integrin alphaIIbbeta3 activation. Curr Opin Hematol (2007) 1.01
Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood (2011) 1.00
Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes. Am J Hematol (2011) 1.00
Surgical and obstetric outcomes in adults with sickle cell disease. Am J Med (2008) 1.00
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br J Haematol (2012) 0.99
Transfusion management in sickle cell disease. Hematol Oncol Clin North Am (2005) 0.98
IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials (2013) 0.96
Fibronectin bridges monocytes and reticulocytes via integrin alpha4beta1. Br J Haematol (2008) 0.96
Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1. Eur J Haematol (2010) 0.96
Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. Haematologica (2008) 0.94
Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy (2006) 0.94
Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU. Blood (2004) 0.93
Red cell antigens as functional molecules and obstacles to transfusion. Hematology Am Soc Hematol Educ Program (2002) 0.93
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol (2013) 0.93
Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood (2012) 0.93
The Lutheran glycoprotein: a multifunctional adhesion receptor. Transfusion (2006) 0.93
Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol (2011) 0.92
Characterization of calcium- and integrin-binding protein 1 (CIB1) knockout platelets: potential compensation by CIB family members. Thromb Haemost (2008) 0.90
Platelet alpha2beta1 integrin activation: contribution of ligand internalization and the alpha2-cytoplasmic domain. Blood (2003) 0.90
Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response. PLoS One (2013) 0.89
A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion. J Biol Chem (2002) 0.89
A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res (2013) 0.88